Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma.
pathology
tumours
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
accepted:
02
08
2020
entrez:
22
9
2020
pubmed:
23
9
2020
medline:
15
10
2021
Statut:
ppublish
Résumé
Craniopharyngioma (CP) is a common refractory tumor of the central nervous system. However, little is known about the expression and clinical significance of B7 family ligands/receptors in CP patients. Thus, we conducted the present study to address this issue in a cohort of 132 CP cases. We mapped and quantified the expression of B7 family ligands/receptors molecules programmed cell death ligand 1 (PD-L1), B7-H3, B7-H4 and V-domain Ig-containing suppressor of T cell activation (VISTA) in 89 adamantinomatous-type CP and 43 papillary-type CP samples using immunohistochemistry and immunofluorescence. Associations between the marker levels, clinicopathological variables and survival were evaluated. The positive rates of PD-L1, B7-H3, B7-H4 and VISTA in the cohort of 132 CP cases were 76.5%, 100%, 40.2% and 80.3%, respectively. The cut-off values of PD-L1, B7-H3, B7-H4 and PD-L1 expression were determined by survival receiver operating characteristic (ROC) package, which was 70, 182, 0 and 20, respectively. Elevated expressions of PD-L1, B7-H3, B7-H4 and VISTA were significantly associated with some clinicopathological characteristics. Kaplan-Meier analysis indicated that higher VISTA expressions correlated with better overall survival (OS) and progression-free survival (PFS) (p=0.0053 and p=0.0066, respectively). Multivariate Cox regression analysis indicated that VISTA was an independent prognostic factor for OS (p=0.018) but not for PFS (p=0.898). We found variable expression of PD-L1, B7-H3, B7-H4 and VISTA proteins in CPs. The results suggest that the expression level of VISTA may be used as an important indicator to predict the OS and PFS of CPs. B7 family ligands/receptors could be potential immunotherapeutic targets when treating CPs.
Sections du résumé
BACKGROUND
Craniopharyngioma (CP) is a common refractory tumor of the central nervous system. However, little is known about the expression and clinical significance of B7 family ligands/receptors in CP patients. Thus, we conducted the present study to address this issue in a cohort of 132 CP cases.
METHODS
We mapped and quantified the expression of B7 family ligands/receptors molecules programmed cell death ligand 1 (PD-L1), B7-H3, B7-H4 and V-domain Ig-containing suppressor of T cell activation (VISTA) in 89 adamantinomatous-type CP and 43 papillary-type CP samples using immunohistochemistry and immunofluorescence. Associations between the marker levels, clinicopathological variables and survival were evaluated.
RESULTS
The positive rates of PD-L1, B7-H3, B7-H4 and VISTA in the cohort of 132 CP cases were 76.5%, 100%, 40.2% and 80.3%, respectively. The cut-off values of PD-L1, B7-H3, B7-H4 and PD-L1 expression were determined by survival receiver operating characteristic (ROC) package, which was 70, 182, 0 and 20, respectively. Elevated expressions of PD-L1, B7-H3, B7-H4 and VISTA were significantly associated with some clinicopathological characteristics. Kaplan-Meier analysis indicated that higher VISTA expressions correlated with better overall survival (OS) and progression-free survival (PFS) (p=0.0053 and p=0.0066, respectively). Multivariate Cox regression analysis indicated that VISTA was an independent prognostic factor for OS (p=0.018) but not for PFS (p=0.898).
CONCLUSIONS
We found variable expression of PD-L1, B7-H3, B7-H4 and VISTA proteins in CPs. The results suggest that the expression level of VISTA may be used as an important indicator to predict the OS and PFS of CPs. B7 family ligands/receptors could be potential immunotherapeutic targets when treating CPs.
Identifiants
pubmed: 32958683
pii: jitc-2019-000406
doi: 10.1136/jitc-2019-000406
pmc: PMC7507895
pii:
doi:
Substances chimiques
B7 Antigens
0
B7-H1 Antigen
0
CD274 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Endocr Rev. 2014 Jun;35(3):513-43
pubmed: 24467716
J Exp Med. 2011 Mar 14;208(3):577-92
pubmed: 21383057
Sci Transl Med. 2018 Jul 18;10(450):
pubmed: 30021886
Cancer Immunol Res. 2019 Jul;7(7):1079-1090
pubmed: 31088847
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32188703
J Neurosurg. 2018 Apr 1;:1-5
pubmed: 29701552
Nat Rev Endocrinol. 2017 May;13(5):299-312
pubmed: 28155902
Nat Commun. 2018 Feb 8;9(1):579
pubmed: 29422527
Neuro Oncol. 2018 Jul 5;20(8):1101-1112
pubmed: 29509940
Nat Rev Endocrinol. 2017 Apr;13(4):195-207
pubmed: 28106152
Mol Cancer Ther. 2017 Jul;16(7):1203-1211
pubmed: 28679835
Clin Cancer Res. 2017 Jan 15;23(2):370-378
pubmed: 27440266
World Neurosurg. 2020 Mar;135:e12-e18
pubmed: 31629137
Clin Cancer Res. 2018 Apr 1;24(7):1562-1573
pubmed: 29203588
Neurosurg Focus. 2016 Dec;41(6):E3
pubmed: 27903126
Immunity. 2018 Mar 20;48(3):434-452
pubmed: 29562194
Clin Cancer Res. 2012 Oct 1;18(19):5304-13
pubmed: 22859719
World Neurosurg. 2017 Jun;102:167-180
pubmed: 28254603
Sci Adv. 2020 Mar 25;6(13):eaay9789
pubmed: 32232155
Nat Commun. 2020 Apr 3;11(1):1669
pubmed: 32245950
Hum Pathol. 2016 Nov;57:1-6
pubmed: 27349304
Clin Cancer Res. 2017 Sep 1;23(17):5202-5209
pubmed: 28539467
Histopathology. 2019 Sep;75(3):421-430
pubmed: 31013360
J Clin Invest. 2014 Feb;124(2):687-95
pubmed: 24382348
Biochem Biophys Res Commun. 2019 Jun 25;514(2):379-385
pubmed: 31043272
Oncoimmunology. 2019 Feb 27;8(5):e1581546
pubmed: 31069143
J Immunother Cancer. 2019 Mar 8;7(1):65
pubmed: 30850021
Nat Med. 2017 May;23(5):551-555
pubmed: 28346412
Br J Cancer. 2019 Jan;120(1):115-127
pubmed: 30382166
Nat Genet. 2014 Feb;46(2):161-5
pubmed: 24413733
Science. 2013 Dec 20;342(6165):1417
pubmed: 24357273
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Immunol Rev. 2017 Mar;276(1):66-79
pubmed: 28258694
J Neurooncol. 2017 Jul;133(3):487-495
pubmed: 28500561
J Neurooncol. 2017 Jan;131(1):21-29
pubmed: 27640198
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373